With no definite cause established, MS has been hypothesized to result from a complex interaction between individual genetic susceptibility and environmental factors that act as triggers.
Approximately 85% of patients with MS initially have a relapsing form of MS (RMS), which is characterized by alternating periodic acute exacerbations of disease activity (relapses) and periods of remission, consisting of partial or complete recovery. If you suffer from RMS, sign up to learn more about a study seeking to compare an investigational RMS medication to an approved RMS medication.
- Must be age 18 to 55 and be diagnosed with relapsing multiple sclerosis
- Must have at least 1 of the following:
- 1 or more documented relapses within the past year
- 2 or more documented relapses within the past 2 years
- 1 or more lesions on an MRI scan within the past year
- Will receive compensation for study-related time
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can also talk to a Meridian enrollment specialist about this study by calling (912) 623-2240.
Submit your information
Meridian Clinical Research
6602 Waters Avenue, Building C
Savannah, GA 31406
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.